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 Abstract 
 
Despite the great advantages in using glycoconjugates for generating a protective 
immunity, the molecular mechanism of T cell epitope recruitment and MHC-II 
presentation has to be clarified. Dissecting the mechanism that controls 
glycoconjugates/peptide-MHC-II interactions will allow defining a rational for a 
better design of glycoconjugate vaccines. It is well accepted that polysaccharides 
function as T cell–independent antigens, since they fail to induce T cell–mediated 
immune responses (IgM to IgG class switching, booster antibody response and T 
cell memory). On the contrary, when a polysaccharide is linked to a carrier 
protein, the protein provides the T cell epitopes that engage the T cell receptor 
(TCR) and trigger the release of cytokines that help the B cell to differentiate and 
proliferate. With the aim to analyze glycoconjugate/MHC-II interactions and 
evaluating the efficacy of glycoconjugate MHC-II processing and presentation, 
different glycoconjugates were synthesized. ß-1,3-glucans oligosaccharides were 
covalently linked to the lysine side chains of recombinant proteins from Neisseria 
meningitidis and Streptococcus pneumoniae. Testing the glycoconjugates in 
mice, we highlighted differences in the immune response probably due to different 
pattern of glycosylation that can lead to a different MHC-II peptide interaction. 
Using proteomic and glycoproteomic approaches, we evidenced differences in the 
pattern and extent of conjugation. Mutated recombinant carriers lacking the 
identified conjugation-sites were produced, conjugated, and tested as carrier in 
mice. This represents a first step in the design of experiments that will provide 
insight in the understanding of the peptide/glycopeptide-MHC-II interaction. 
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1. Introduction 
 
1.1  History of vaccination 
 
Vaccination represents one of the key developments in fighting infectious 
diseases. It is estimated to prevent 2.5 million of deaths each year1. The history of 
vaccine began in 1796 when Edward Jenner discovered that people could be 
protected against smallpox by being previously injected with the cowpox virus. 
Jenner’s idea of using a poxvirus from animal to prevent smallpox was essentially 
based on believing that an agent virulent for animals might be attenuated in 
human2. The concept of attenuation (i.e. bacteria killed by heat or chemical 
treatment) was well described and applied by Pasteur almost 100 years later. At 
the end of the 19th century, he successively developed attenuated rabies virus in 
animals and humans, anthrax in sheep, and Pasteurella multocida in chicken3. 
The concept of isolation, inactivation and injection of a causative microorganism, 
developed by Pasteur, provided the scientific basis for vaccinology and its 
evolution during the 20thcentury. During the 1900s, many discoveries and 
successes have been registered on vaccine development and the effectiveness of 
vaccination has been proved on the human health. The impact on public health 
has been clearly proven by the eradication of smallpox and the reduction of 
mortality and morbidity caused by various diseases. Over the last three centuries, 
vaccinology has enabled the realization of numerous vaccines; furthermore 
modern approaches appear promising for the selection and the design of novel 
protective antigens that will increase the number of preventable diseases in the 
future. Understanding the concept of ‘antigen’ and that the whole pathogen is not 
always needed to induce immunity, lead to increase vaccines’ safety and 
efficacy4.  
As reported in Table 1, the development of vaccines has involved different 
approaches (e.g the traditional whole pathogens live attenuated; killed or 
inactivated pathogens; and toxin isolated from the pathogen and inactivated). 
Subunit vaccines such as proteins produced by recombinant DNA or from 
genetically detoxified microorganism as well as capsular polysaccharides (CPSs), 
alone or covalently linked to a carrier protein (glycoconjugates), have been used.  
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Live attenuated Killed whole organisms 
Purified proteins or 
polysaccharides 
Genetically engineered 
18th Century 
   
19th Century 
Rabies (1885) 
 
Typhoid (1896) 
Cholera (1896) 
Plague (1897) 
  
Early 20th Century, first half 
Tuberculosis (bacilli 
Calmette-Guérin) (1927) 
Yellow fever (1935) 
Pertussis (1926) 
Influenza (1936) 
Rickettsia (1938) 
Diphtheria toxoid (1923 
Tetanus toxoid (1926) 
 
20th Century, second half 
Polio (oral) (1963) 
Measles (1963) 
Mumps (1967) 
Rubella (1969) 
Adenovirus (1980) 
Typhoid (SalmonellaTY21a) 
(1989) 
Varicella (1995) 
Rotavirus reassortants 
(1999) 
Cholera (attenuated) (1994) 
Cold-adapted influenza 
(1999) 
Polio (injected) (1955) 
Rabies (cell culture) (1980) 
Japanese encephalitis 
(mouse brain) (1992) 
Tick-borne encephalitis 
(1981) 
Hepatitis A (1996) 
Meningococcal conjugate 
(group C) (1999) 
Anthrax secreted proteins 
(1970) 
Meningococcus 
polysaccharide (1974) 
Pneumococcus 
polysaccharide (1977) 
Haemophilus 
influenzae type B 
polysaccharide (1985) 
H.influenzae type b 
conjugate (1987)* 
Acellular pertussis (1996) 
Hepatitis B (plasma derived) 
(1981) 
Hepatitis B surface antigen 
recombinant (1986) 
Lyme OspA (1998) 
Cholera (recombinant toxin 
B) (1993) 
21st Century 
Rotavirus (attenuated and 
new reassortants) (2006) 
Zoster (2006) 
Japanese encephalitis 
(2009) (Vero cell) 
Cholera (WC only) (2009) 
Pneumococcal 
conjugates*(heptavalent) 
(2000) 
Meningococcal conjugates* 
(quadrivalent) (2005) 
Pneumococcal 
conjugates*(13-valent) 
(2010) 
Human papillomavirus 
recombinant (quadrivalent) 
(2006) 
Human papillomavirus 
recombinant (bivalent) 
(2009) 
Human papillomavirus 
recombinant (9-valent) 
(2014) 
Meningococcal group B 
proteins (Fh-factor) (2014) 
Meningococcal group B 
(reverse vaccinology) 
(2015) 
*Capsular polysaccharide conjugated to a carrier protein 
 
Table 1: Outline of the development of Human vaccine
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1.2  Carbohydrate based vaccines 
 
Carbohydrates are the most abundant and structurally diverse molecules in 
nature. They are largely present on pathogens surface such as viruses, bacteria, 
parasites and fungi. They can form an amorphous layer of extracellular 
polysaccharide surrounding the cell that may be further organized into a distinct 
structure termed capsule6. Capsular polysaccharides (CPs) have several 
functions: they protect bacteria from desiccation during transmission from host to 
host and mediate adhesion of the bacteria to surfaces and to each other. 
Polysaccharides can also confer resistance to the specific/nonspecific host 
immunity allowing the pathogen to escape the host immune system by either 
mimicking the host structures or conferring resistance to the complement-
mediated killing7. Even though a small set of polysaccharides are poorly 
immunogenic, most of them can elicit an immune response and be used as 
pathogen signatures. 
CPs are homo or heteropolymers, composed of monosaccharide repeated units 
joined with glycosidic linkages7. These can be recognized by the immune system 
and induce an immune response8. Avan and Heidelberg already described this 
effect in the 1920, showing that Streptococcus pneumoniae CPs are immune 
reactive components9-10. However, the parallel introduction of antibiotics put aside 
the development of carbohydrate vaccines. Indeed, the first polysaccharide 
vaccine, PneumoVax (Merck & Co.), was introduced only in the 1983. It consisted 
of CPs extracted from 14 pneumoniae serotypes. Today, the Pneumo Vax 23 
includes 23 out of 90 known serotypes.  
(Merck & Co., Inc. Pneumovax 23 (pneumococcalvaccinepolyvalent). 
Merckwebsite [online] http://www.merck.com/product/usa/pi_circulars/p/ 
pneumovax_23/pneumovax_pi.pdf) 
Unfortunately, CPs vaccines have failed to induce an immune memory response 
in young children below two years of age and only partially have induced 
protection in the elderly and patients with chronic diseases11. Moreover, every few 
years, a boost is needed regardless of age because of the vaccine’s inability to 
induce immune memory12. The absence of immune memory is mainly due to the 
mechanism involved in the carbohydrate immune response. Antigens can follow 
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different pathways of internalization and processing (Figure 1). Typically, proteins 
are thymus –dependent antigens (Td), in which the antigen is internalized and 
processed by an antigen presenting-cell (APC). Then, the antigen-peptides are 
presented to the MHC-II complex molecules for the binding with an antigen-
specific CD4+T cells via their specific T cell receptor (TCR)13,14. The activated 
CD4+T cells promote the release of cytokines leading to B cell proliferation, 
maturation, isotype switching and, immunological memory formation15 (Figure 
1.b). CPs act as thymus independent antigen (Ti) and do not active T cells16-17. 
They are not presented on the MHC-II but directly activate B cell independently of 
the interaction of the CD4+ T-cells, avoiding the affinity maturation and isotype 
switching, as well as the generation of T and B cell memory18 (Figure 1.a). CD4+ 
T-cell epitopes must be usually provided in the form of a carrier protein in order to 
recruit CD4+T-cell for antibody responses to the glycan. Avery and Goedel, as 
early as 1931, reported that the immunogenicity of carbohydrates could be 
enhanced when the glycans were conjugated to protein scaffolds19. Due to the 
lake of immune-memory with the vaccination of pure CPs the studies moved 
towards the development of glycoconjugates. 
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Figure 1 - Pathways of immune cell activation by protein: (1.a) T-cell-independent pathway. 
(1.b)T-cell-dependent pathway. The generation of immune response by the T-cell-dependent 
pathway requires the presence of both B-cell and T-cell epitopes. After the recognition of the B-
cell epitope by BCR, the B-cell will process and present the T-cell epitope to the MHC class II 
molecule. Meanwhile the uptake and processing by professional APCs lead to the presentation of 
the T-cell epitope on MHC class II to naïve T-cells that will be activated for the recognition of the 
antigen-primed B-cell, releasing cytokine signals required for the switching of B-cells into plasma 
cells. The T-cell-independent response occurs instead with the activation of the B cell via the 
BCRs, maturating into plasma cells after the release of cytokine signal
20
 (Adapted from Kumar S. 
et al.). 
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1.3  Glycoconjugate vaccines 
 
It is now well known that immunization with capsular polysaccharides covalently 
linked to an immunogenic protein carrier (Glycoconjugates) induces memory 
response against the encapsulated bacteria, even among people in high risk 
groups (neonates, children under two years of age, and elderly).21 In 1930, Avery 
& Goebel were pioneers in demonstrating the ability to enhance the 
immunogenicity of polysaccharide19. The authors showed that the poor 
immunogenicity of the S. pneumoniae type III polysaccharide could be enhanced 
by conjugation of the polysaccharide to a carrier protein.  
Earlier studies in 1980s led to the development of the first licensed conjugate 
based vaccine, in which a capsular polysaccharide of H.influenzae type b (Hib) 
was covalently conjugated to diphtheria toxoid (DT) protein22. The success of the 
Hib conjugate has accelerated the design of other capsule-based vaccines. For 
two decades, conjugate vaccines against Meningococcus serogroup C, and 
against seven serotypes of pneumococcus were licensed; in particular in the past 
decade, the same technology was used to develop vaccines against 
meningococcus serogroup A, C, Y, W23,24 and against six extra pneumococcus 
serotypes leading to a 13-valent pneumococcal conjugate vaccine25.  
Currently, the carrier proteins used for glycoconjugation are typically proteins 
obtained in sufficient amount and purity. These are generally not toxic and stable 
under the chemical conditions applied during the conjugation procedures (pH, 
concentration, ionic strength, temperature)26. Specifically, the most used carrier 
proteins consist in denatured bacteria toxoids, i.e. tetanus toxin (TT), diphtheria 
toxin (DT) and a nontoxic DT mutant, CRM197
27. Different chemistries can be 
applied for the conjugation of polysaccharides to these carrier proteins. All of 
them take advantage of a suitable spacer and a functional group for conjugation 
that can be aldehyde, thiol, activated ester, hydrazide, carboxyl acid or amine that 
can be either presented or generated on the polysaccharides for the subsequent 
linkage to the protein28,29. Until very recently, non-specific methods for site-
conjugation of the glycan antigen have been available and most of the 
glycoconjugates still result in different glycoforms. This heterogeneity may show 
differences in the immunological properties and pharmacokinetic due to a 
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different epitope density and glycosylation sites. Hence, increasing attentions 
have been putting on the chain length, presence of ramification points and charge 
on the polysaccharide motif. A great effort has been done to improve the 
conjugation chemistry and the type of spacer employed, which may direct the 
immune response away from the antigen carbohydrate. At the present, 
Glycoconjugates represent a promising strategy to combine the antigenic of 
polysaccharide with the use of a carrier protein for the induction of a T cell 
dependent response based on the carrier protein-derived peptide presentation by 
the MHC-II molecules on the APCs.  
 
1.3.1 Characteristics of Carriers proteins in conjugate vaccines 
Production of glycoconjugate vaccines involves the chemical conjugation of 
glycans to an immunogenic carrier protein to elicit a strong and long-lasting 
immune response (T-cell dependent). To date, 5 carrier proteins have been used 
in licensed conjugate vaccines: meningococcal outer membrane protein complex 
(OMPC), diphtheria toxoid (D), tetanus toxoid (T), H. influenzae protein D (HiD) 
and CRM197 a genetically modified cross reacting material of diphtheria toxin. All 
of these carriers are effective in increasing vaccine immunogenicity but they differ 
in the quantity and avidity of antibodies produced, the ability to carry multiple 
antigens in the same product and the efficiency to be given with other vaccines30. 
The first-generation of carrier proteins used are represented by diphtheria toxin 
and tetanus toxin that required detoxification with formaldehyde. They were 
initially selected as carriers because of safety track record established over 
decades of vaccination against tetanus and diphtheria31. The OMPC of N. 
meningitis serogroup B is used as carrier for Hib conjugate developed by Merck. 
Protein D, which derived from non-typeable H. influenza (NTHi), is used as carrier 
for most of polysaccharides included into the multivalent pneumococcal conjugate 
vaccine by GSK. At the moment, the most wildly used and highly effective carrier 
protein is the CRM197, a non-toxic mutant of diphtheria toxin. It differs from the 
wild-type diphtheria toxin in that a point mutation at the amino acid position 52 
substitute glycine with glutamic acid, which eliminates enzymatic activity and 
toxicity32. CRM197 shows several advantages as protein used for the conjugation: 
it is nontoxic and has more lysine side-chains available for conjugation comparing 
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to the diphtheria toxin. It is still extensively used as carrier for licensed conjugate 
vaccines against Streptococcus pneumoniae, Neisseria meningitis and H. 
influenza type b. Among the 5 carriers, CRM197 shows a greater versatility when it 
is used in combination with other vaccines and also on multiple polysaccharides 
conjugates30. 
 
1.3.2 Glycosylation and antigen processing 
1.3.2.1 Major histocompatibility complex structure 
As already described in this introduction, the MHC-II molecule is involved in the 
regulation of the adaptive immune system against invading pathogens detecting 
the presence of foreign pathogens. 
The MHC-II histocompatibility complex is a heterodimer composed of two 
membrane chains, α and β. The proximal membrane domains (α2 and β2) are 
folded into Ig-like domain and a trans-membrane sequence for anchoring. The 
distal membrane region α1 and β1 are folded together in a single groove-shape, 
which is defined by a β sheets floor and two parallel helical sides33.  
The MHC-II molecule binds peptides of around 12-24 aa in length34. It is possible 
to distinguish two main sub structures of interaction: a central core of binding 
represented by the groove, which establishes a nonameric binding region and, 
residues outside the nonameric binding region called peptide flanking residues 
(PFRs), which is also able to interact with the MHC-II complex (Figure 2). 
The peptide flanking residues, not bound in the groove, can enhance the binding 
and stability conformation of the complex35. It is also widely accepted that they 
can contribute to the T cell mediated peptide-MHC-II recognition, and influence 
the TCR activation as well as the residues in the core binding region36. 
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37
Figure 2 - structure and peptide 
interaction to the MHC-II: Protein crystal 
structure of MHC-II molecule (HLA-
DRB1*0101) interacting with peptide (PDB 
id: 1AQD). The α-chain is shown in dark 
blue, while the β-chain in grey. The peptide 
(GSDWRFLRGYHQYA) is shown as sticks: 
in red the peptide binding core and in pink 
the flanking amino acids.  
 
 
 
 
1.3.2.2 Peptide glycopeptide antigen presentation 
The capacity of the T-cell-dependent antigen to recruit CD4+T cells during the 
primary immune response represents a critical step to the generation of a 
memory immune response38. The T cell dependent antigen can be internalized by 
the B cell using its B cell receptor (BCR) and then processed and presented 
within the MHC-II on the surface of the B cell13. This allows the B cell to interact 
with the related CD4+T cells following the recognition of the peptide/MHC-II 
complex by the T-cell receptor (TCR). In contrast, T cell independent type 2 (TI-2) 
antigen including isolated polysaccharides of encapsulated bacteria such as 
Neisseria meningitidis and Streptococcus pneumoniae cannot, in general, be 
presented to the MHC-II complex and are thus unable to recruit CD4+T cells for 
the classical isotype switching of memory B cells39. Conjugates vaccines, 
targeting encapsulated bacteria, are able to overcome the limitation of 
polysaccharide immune response through their covalent linkage to an 
immunogenic carrier protein for the presentation to the MHC-II complex40. As 
previously discussed, the current dogma states that polysaccharides act as T cell-
independent antigens. Being highly hydrophilic, they cannot dock to the groove of 
the MHC molecules; therefore, they cannot be presented to the T cell receptor41 
(Figure 3.a). Nevertheless, some studies suggest that the polysaccharide can be 
presented to the MHC-II complex after depolymerization within the APC 
endosomes/lysosomes by nitric oxide-derived reactive nitrogen species (RNs) 
and/or superoxide-derived reactive oxygen species (ROSs)42,43.Few years ago, 
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Avici et. al.44described also a new molecular mechanism, in which the 
glycoconjugates internalized in the B cells are processed and then presented to 
the MHC-II as glycopeptides.  
The presentation of the carbohydrate motif is possible thanks to the peptide that 
act as an anchor binding to the MHC-II. This new proposed mechanism also 
contributes to indicate that the carbohydrate can interact with a specific 
carbohydrate specific T cell clone (Figure 3.b). It is necessary to specify that only 
small saccharides form 1 to 4 carbohydrate units could be inserted within the 
binding site of T cell receptor45, whereas the B cell receptor could theoretically 
bind up to six units46. Even though 4-6 repeating units of carbohydrate can 
interact with the T cell receptor, the glycoconjugate vaccines present on the 
market show a different scenario. Except for the Cuban anti–H influenzae47 
vaccine, the glycoconjugate vaccines, commercially available, present safety 
issue due to the inherent lot-to-lot variability. From an immunological point of 
view, the carbohydrate structures on these glycoconjugates are too large and 
randomly distributed at the carrier surface, limiting the possibility that 
carbohydrate processed in the lysosome could result in a sufficient quantity of 
homogenous glycopeptide suited for the T cell binding48. 
This complex mechanism is still under discussion and the current literature is not 
able to clarify the mechanism of glycan processing and carrying yet.  
 
Figure 3 - Model proposed for antigen processing and presentation
 41
: (3.a) Current dogma: 
The peptide epitope is processed, presented by the MHC-II and recognized by a peptide-specific 
T cell; (3.b) the new mechanism presented by Avci et al.: the peptide presented to the MHC-II acts 
as an anchor for the sugar epitope, allowing the presentation of the sugar epitope to a 
polysaccharide-specific T cell. (Adapted from Rappuoli et al. 2011).  
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1.4 Background for the study 
 
In a previous study performed in the host laboratory, a group of twenty-seven 
proteins, derived from different pathogens and expressed as recombinant 
proteins in E. coli, were conjugated to the polysaccharide Laminarin (Lam)49. Lam 
is a β-(1, 3) glucan with β-(1, 6) branches, that has been studied as vaccine 
candidate against C. albicans infections50-51-52. The carrier proteins of this study 
were selected using the following criteria: 
 not expected toxicity based on available information  
 solubility in physiological buffers at concentrations of 0.4–6 mg/mL 
 presence of a sufficient number of lysines for conjugation 
 proteins with molecular weight between 40 and 100 kDa 
These recombinant carriers were conjugated with Lam modified at its end 
reducing group. The succinimido diester of adipic acid (SIDEA) was used as 
linker obtaining in such a way a terminal succinimido ester group available to 
react with the primary amines on the side-chain of the lysine on the proteins.  
The conjugates were tested in mice without the use of any adjuvant highlighting 
the intrinsic value of the carrier only. Seven proteins (pathogenic E. coli Orf3526 
and Upec-5211, S. pneumoniae spr907, spr1418, and spr1875 N. meningitidis 
GNA2091-fHbp53,and S. agalactiae RrgB I-II-III, were demonstrated to function as 
proteins carrier for Lam with a level of anti-Lam antibodies inferior or equal to 
1145 (GMT ± 95% CI) which is comparable to the level of anti-Lam antibodies 
produced by CRM197–Lam. The only conjugate able to induce an IgG anti-Lam 
antibody titer significantly higher than the CRM197–Lam was the spr96/2021. 
Spr96/2021 is a recombinant fusion composed of two pneumococcal proteins: 
spr2021 (secreted PcsB protein) and spr0096 (LysM protein) 54-55. Curiously,  no 
response was induced by the spr0096 conjugate and very low by the spr2021 
one, indicating that some characteristics derived from the fusion of the two 
proteins were critical for the carrier activity. By conjugated to meningococcal 
serogroup C (Men C) oligosaccharides, the spr96/2021 conjugate induced anti 
Men C polysaccharide IgG titers comparable to those developed by CRM197 
conjugate; while Upec-5211, Orf3526, and spr1875 conjugate responses were 
comparable to the positive control and RrgB I-II-III, spr907, spr1418 and 
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GNA2091-fHbp conjugates were inferior to the control. Moreover, spr96/2021 was 
also tested as carrier for serogroup A, W and Y meningococcal saccharides, 
which are currently part of licensed vaccines56-57 and serogroup meningococcal X 
polysaccharide (Men X), recently identified as a potential candidate for vaccine 
development58, at a comparable level to CRM197 conjugates
49.  
As already mentioned in this section, several factors are important in determining 
the ability of a protein to work as carrier, but the main role of the carrier in 
glycoconjugate vaccines is to provide T-cell epitopes which bind to the class II 
MHC. At the time, the data were published and no correlation between the 
numbers of MHC-II predicted peptides and IgG production was identified. 
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2. Aim of the study 
 
Glycoconjugates have been demonstrated to very safe and efficient vaccines. In 
spite of their success, their design is still very empirical, and their mode of action 
is not well understood. In particular, the influence of the glycosylation on the 
molecular mechanism of T cell epitope recruitment and MHC-II presentation has 
to be clarified. Dissecting the mechanism that controls glycopeptide/peptide MHC-
II interactions will allow defining a rational for a better design of glycoconjugate 
vaccines. For this purpose, the aim of the thesis is to: 
 Draw a hypothesis on the parameters able to influence the efficacy of a 
protein to function as a carrier for glycoconjugate vaccine by comparing 
production of anti-saccharide IgG of a large number of potential carriers 
reported in literature to the presence of prediction of MHC-II-presenting 
peptides on these carriers.  
 Select a carrier protein model to validate the hypothesis that efficacy of a 
protein carrier is correlated to predicted MHC-II-presenting peptides with high 
affinities and that when these predicted MHC-II-presenting peptides contained 
lysine residues, these ones should not be conjugated. 
 Use mass spectrometry (proteomics and structural mass spectrometry) to 
assess the pattern and extent of conjugation of the carriers (S. pneumoniae 
carrier protein spr2021 alone or in fusion constructs). 
 Correlate the efficacy in mice of the S. pneumoniae carrier protein spr2021 
with the absence of conjugation on lysine residues present in predicted MHC-
II-presenting peptides, by assessing the pattern and extent of conjugation of 
the carrier alone or in fusion constructs by proteomics. 
 Based on the hypothesis and analytical data, construct and validate mutated 
protein carriers with a higher efficacy in terms of IgG production. 
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3. Materials and methods 
 
3.1 Mutants’ generation of GNA2091-fHbp, spr2021/96 and 
spr2021 
 
Site-directed mutagenesis on GNA2091-fHbp, spr2021/96 and spr2021 DNA 
sequences was performed to produce the set of mutants listed below. Mutants 
were constructed using the polymerase incomplete primer extension cloning 
method (PIPE). The mutagenesis reactions were transformed into chemically 
competent E. coli Mach1™-T1R (Thermo Scientific). After sequencing, each 
plasmid was used to chemically transform E. coli BL21(DE3)  T1R cells (NEB) for 
protein production.  
spr2021 mutant Plasmid characteristics 
Spr2021_Lys204Arg 
pET151/D-TOPO derivative for expression of recombinant spr2021, 
containing a Lys204Arg mutation, AmpR 
Spr2021_Lys248Arg 
pET151/D-TOPO derivative for expression of recombinant spr2021, 
containing a Lys248Arg mutation, AmpR 
Spr2021_Lys204Arg_Lys246A
rg_Lys248Arg 
pET151/D-TOPO derivative for expression of recombinant spr2021, 
containing a Lys201Arg, Lys256Arg,Lys248Arg mutations, AmpR 
Spr2021/96 mutant Plasmid characteristics 
Spr2021/96_Lys172Arg 
pET21b(+), derivative for expression of recombinant spr2021, containing a 
Lys172Arg mutation  AmpR 
Spr2021/96_Lys216Arg 
pET21b(+), derivative for expression of recombinant spr2021/96, containing 
a Lys216Arg mutation  AmpR 
Spr2021/96_Lys172Arg_Lys2
16Arg 
pET21b(+), derivative for expression of recombinant spr2021/96, containing 
a Lys172Arg and Lys216Arg mutations  AmpR 
Spr2021/96_Lys172Arg_Lys2
14Arg_Lys216Arg 
pET21b(+), derivative for expression of recombinant spr2021/96, containing 
a Lys172Arg, Lys214Arg and Lys216Arg mutations  AmpR 
Spr2021-CRM197-96 
 
pET21b(+), derivate for expression of recombinant  spr2021/96 in which the 
linker  GSGSGGGG have been substituted with GIALSSLMVAQAIPLVG , 
AmpR 
GNA2091-fHbp mutant Plasmid characteristics 
GNA2091-CRM197-fHbp 
pET24 derivative for expression of recombinantGNA2091-fHbp,  which the 
linker  GSGSGGGG have been substituted with GIALSSLMVAQAIPLVG, 
AmpR 
GNA2091-2021-fHbp 
pET24 derivative for expression of recombinantGNA2091-fHbp,  which the 
linker  GSGSGGGG have been substituted with 
GRRASQQQSVLASANTG, AmpR 
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3.1.1 Protein expression and purifications 
Escherichia coli strain BL21(DE3) cells (Novagen) were used for protein 
expression. Cells were grown using BioSilta medium (Enpresso B Animal-free 
growth systems), at 30 °C for 12 h, and recombinant protein expression was 
induced by the addition of 1mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 
25 °C. After an additional 24 h, cells were harvested by centrifugation and re-
suspended in 50 mM NaH2PO4, 250 mM NaCl, pH 7.4, followed by lysis via 
sonication (Qsonica Q700). Cell lysates were clarified by centrifugation at 10000 
g for 30 min, and the supernatant, containing the expressed protein, was filtered 
using a 0.22 μm membrane filters (EMD Millipore filters) before starting the first 
chromatography step. All proteins were purified at room temperature (RT, 25 °C) 
using an AKTA purifier 100 system (GE Healthcare). A first purification step by 
using Co2+ affinity chromatography (5 mL HiTrap TALON crude, GE Healthcare) 
was performed for those proteins that presented His tag motif. Conversely, a first 
purification step by ionic exchange chromatography, either anionic or cationic 
depending on the isoelectric point of the proteins by 5 mL SP or Q HP (GE 
healthcare) columns, was carried out if the His tag motif was not evidenced.. A 
second step of purification was performed using Hydrophobic chromatography 
(4.7 mL Hiscreen Phenyl HP), followed by size-exclusion chromatography on a 
Superdex 200 16/60 column equilibrated in 20 mM NaH2PO4, 50 mM NaCl, pH 
7,4). The purity of the proteins was checked using 4–12% SDS–PAGE gradient 
gels in MES buffer. The content of lipopolysaccharide (LPS) on the purified 
protein was checked using the Endosafe nexgen-PTS system (Charles River). 
When the content of LPS was out of the range, they were removed using either Q 
HP (GE healthcare) columns or EndoTrap Red columns (Hyglos). 
 
3.1.2 Differential Scanning Calorimetry 
The thermal stability of the proteins was assessed by differential scanning 
calorimetry (DSC) using a MicroCal VP-Capillary DSC instrument (GE 
Healthcare). A protein concentration of 0.4 mg/mL in PBS buffer was used to 
prepare samples. The DSC temperature scan ranged from 20 °C to 140 °C, with a 
thermal ramping rate of 150 °C/h and a 4 s filter period. Data were analysed by 
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subtracting the reference buffer data through the use of the Origin 7 software. The 
mean values of the melting temperature (Tm) were determined. 
 
 
3.2 Preparation of oligosaccharide 
 
3.2.1 Reductive amination 
Laminarin (Sigma-Aldrich) was treated by reductive amination to introduce an NH2 
group at the reducing end of the sugar through the use of the following conditions: 
Polysaccharide with a final concentration of 4 mg/mL was added with sodium 
acetate to a final concentration of 300 g/L. Sodium cyanoborohydrate was added 
in a quantity of 1/5 mole of ammonium acetate. The pH of the reaction was 
checked and constrained between 7.4 and 7.6. The polysaccharide was 
incubated for 5 days at 50 °C. The aminated laminarin was then purified from the 
reaction mixture by Tangential fast flow on regenerated cellulose membrane (cut-
off 1 kDa; Sartorius Stedim) and the amount of amino group introduced was 
determined. Amino group was determined by colorimetric assay as described in 
paragraph 3.7 
 
3.2.2 Derivatization of Laminarin amino polysaccharide to active ester 
The purified aminated polysaccharide was dried under-vacuum and re-suspended 
to a concentration of amine of 40 µM/mL in H2O:DMSO 1:9 (v/v). Thriethylamine 
was added in a molar excess of 5 fold compared to the primary amine, and 
Succinoamido diester of adipic acid (SIDEA) was added in a 12 fold molar excess 
compared to the primary amine. The reaction was kept under gentle stirring for 2 
h at room temperature. The activated polysaccharide was purified form the 
reagents by precipitation with ethylacetate. The precipitate was washed 10 times 
and then dried under vacuum. Content of N-hydroxysuccinimide ester introduced 
was determined as described in paragraph 3.7 
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3.3 Conjugation of polysaccharide with carrier proteins and 
purification of glycoconjugate 
 
The SIDEA activated Laminarin was conjugated to the carrier proteins. The 
conjugation was carried out in 20 mM NaH2PO4, 50 mM NaCl pH 7.2; the reaction 
was carried overnight with gentle stirring. The molar ratio carrier protein: active 
ester polysaccharide was kept at 20:1. The conjugates obtained were purified 
from the unreactive sugar by ultrafiltration on polyethersulphone membrane with a 
cut-off of 10 kDa (Vivaspin, Millipore) using PBS pH 7.4. 
 
3.3.1 Determination of the total and free saccharide in the conjugates 
preparation 
Total and free laminarin saccharide was determined by anionic exchange pulsed 
amperometric detection (HPAE-PAD, (Dionex ICS 3000 system). 
 
3.3.1.1 Laminarin saccharide determination 
Total laminarin was determined by HPAE-PAD analysis using a CarboPAC1 
column coupled to a CarboPAC1 guard column connected to a Dionex ICS3000 
system. Sample was treated with 2 M trifluoroacetic acid (TFA), heated at 100 ºC 
for 4 h in a closed screw-cup tube. The sample was then dried under vacuum, 
dissolved in water and then filtered. The separation was performed with a flow 
rate of 1 mL/min using an isocratic elution of 40 mM NaOH for 12 min and 
followed by a washing step of 5min with 500 mM NaOH. The chromatographic 
data were processed using Dionex ChromeleonTM software. The glucose was 
used for generating the calibration curve, at a concentration range of 0.5–10.0 
μg/mL.  
 
3.3.1.2 Determination of laminarin free saccharide content in the conjugates 
preparations 
Determination of free saccharide in the conjugate formulation was determined 
through the separation of the free saccharide and the conjugated by using the 
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cartridges Bioselect C4 300 Å. The saccharide quantification has been then 
performed as described in the previous paragraphs. 
 
 
3.4 Protein and glycoconjugate characterization 
 
3.4.1 Entire protein mass analysis  
To verify the molecular of the proteins and mutants produced entire mass was 
performed. The samples were diluted with formic acid (Sigma-Aldrich) 0.1%, and 
injected on a Waters SynaptG2 ESI mass spectrometer equipped with a standard 
ESI source (Waters®). The protein samples were trapped and desalted for 2 min 
at a flow rate of 800 µL/min using a Protein Micro Trap column (Michrom 
BioResources) equilibrated with 100% buffer A (0.1% formic acid in water (v/v)). 
Proteins were directly eluted into the mass spectrometer at a flow rate of 600 
µL/min with 55% solvent B (acetonitrile/water, 0.1% formic acid (v/v)). The ESI 
source was set as following: capillary voltage, 3.0 kV; sampling cone, 35V; 
extraction cone, 4 V; source temperature, 80 °C; desolvation gas flow and 
temperature, 600 L/h and 180 °C, respectively; cone gas flow, 20 L/h; trap 
collision energy, 4 V. Mass spectra were acquired in resolution mode (m/z 100-
2000) and the calibration was performed in positive mode using a 2 mg/mL 
cesium iodide (Sigma) solution prepared in 50% isopropanol. The spectra were 
processed with MassLynx 4.1 software (Waters). 
 
3.4.2 Chemical deglycosylation 
For the identification of the sites of conjugation a chemical method using 
Trifluoromethanesulphonic acid (TFMSA) for a specific solvolysis of glycosidic 
bonds was chosen for the removal of carbohydrates from the glycoconjugates. In 
detail the glycoconjugates were desalted by ultrafiltration using a 
polyethersulphone membrane with a cut-off of 10 KDa (Vivaspin, Millipore) and 
then freeze-dried for at least 24 h. Dried glycoproteins were treated with pre-
cooled TFMSA containing 10% (v/v) anisole in anhydrous condition and incubated 
at -20 ºC for 2 h. The TFMSA/conjugates solution is then neutralized in a dry ice/ 
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ethanol bath, by a 40% pyridine/water (v/v) a ratio v/v 3:1 to the volume of 
TFMSA initially added. The de-glycosylated carriers were isolated from the 
reagents by dialysis against a solution of 20 mM Sodium phosphate pH 7.4.  
 
3.4.3 Glycoconjugates digestion and LC-MS/MS analysis   
Glycoconjugates and de-glycosylated proteins were characterized by LC-MS/MS 
analysis. 25 µg of sample was denatured 10 min at 100 ºC with Rapigest® 
(Waters). If a protein contains disulphide bridges 5 mM DTT were added to the 
denaturation solutions for the sequent alkylation of side chain of cysteine, 
iodoacetamide at 50 mM final concentration was added and the reaction was 
allowed to proceed in the dark for 30 min.  
Trypsin (Gold Mass Spectrometry Grade Promega®) was added in a ratio 
protein/enzyme of 1:20 (w/w). Digestion was carried out at 37 °C overnight. The 
digestion was stopped by adding formic acid FA at 0.1% (v/v) solution to acidic 
pH (pH~2).  
The peptide mixtures were then desalted using OASIS cartridges (Waters) 
following the manufacturer's protocol. Desalted peptides were concentrated with a 
Speedvac (Eppendorf) and re-suspended in 50 μl of 0.1% (v/v) FA.  
Peptides solution were analyzed by LC-MS/MS performed on a nanoAcquity 
UPLC system (Waters®) coupled a Waters SynaptG2 ESI mass spectrometer 
equipped with a nanospray source (Waters®). Samples were loaded onto a trap 
Symmetry C18 180 μm x 20 mm, 5 μm (Waters®) using a full loop injection at a 
flow rate of 600 nL/min in a mobile phase A (0.1% FA). Peptide were than 
separated on a nano Acquity UPLC Peptide BEH C18 Column 75 μm x 100 mm 
(Waters®) using a 70 min gradient 3-98% mobile phase B (98% (v/v) ACN, 0.1% 
(v/v) FA) at a flow rate of 300 nL/min.  
An automated data-dependent acquisition (DDA) using the Mass Lynx software 
(waters) was used for the acquisition of the eluted peptides. An MS survey scan 
was used to automatically select multi charged peptides over the m/z ratio range 
of 300–2,000 for further MS/MS fragmentation. Up to eight different peptides were 
individually subjected to MS/MS fragmentations following each MS survey scan. 
After data acquisition, individual MS/MS spectra were combined, smoothed, and 
centroided using ProteinLynx, (Waters®) to obtain the peak list file (pkl).  
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Peptide and glycopeptides identification was carried from the generated peak list 
using the Mascot engine software (Matrix Science). Search parameters were: 
i. Fixed modification was the carboamidomehtylation on the Cysteine 
residues (when cysteine alkylation was performed).  
ii. Variable modifications for carriers and deglycosylated carriers were: 
methionine oxidation, glutamine and asparagine deamidation; SIDEA-Glc 
(+291,13180 Da) was added to the variable modification for the analysis of 
the deglycosylated carriers. 
iii.  Peptide mass tolerance as 0.5 Da, peptide MS/MS tolerance as 0.5 Da, 
missed cleavage = 2, ion charge states: +2, +3, +4). Only significant hits 
were considered as defined by the Mascot scoring and probability system 
>15. 
 
3.4.4 Epitope Mapping and HDX 
3.4.4.1 Peptidic map 
Neisseria meningitidis proteins GNA20191-fHbp and fHbp (which do not contain 
cysteine residue) or Streptococcus pneumoniae proteins spr2021, spr96-2021 
and spr2021-96 (which contain disulfide bridge) were treated for 1 h at 60 ºC with 
2 M guanidinium chloride or 3.5 M Urea, 0.4 M TCEP, 0.2 M Guanidinium 
chloride. Following this denaturating treatment, proteins were subsequently 
injected into nanoACQUITY ultra-performance liquid chromatography system for 
the digestion, that was performed online for 2.5 min at 20 °C with a pepsin column 
(Poroszyme® Immobilized Pepsin Cartridge). The generated peptides were 
trapped, concentrated and desalted using a pre-column (VanGuard BEH 1.7 μm, 
2.1x5 mm) and separated using a ACQUITY UPLC BEH C18 reverse phase 
column, 1.7 μm, 1.0x100 mm (Waters) with a linear gradient from 3 to 45% of 
acetonitrile/water, 0.1% formic acid over 6.8 min at 40 μl/min. The mass spectra 
were acquired in a resolution mode (m/z 100-2000) on a Waters SynaptG2 mass 
spectrometer equipped with a standard ESI source. Mass accuracy was ensured 
by continuously infusing a GluFib solution (600 fmol/μL in 50% acetonitrile, 0.1% 
formic acid) through the reference probe of the ESI source. The identity of each 
peptide was confirmed by MSe analyses. MSe was directly performed by a 
succession of low (6 V) and high collision (25 V) energies in the transfer region of 
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the mass spectrometer. Data were processed using Protein Lynx Global Server 
3.0 (Waters). The DynamX 3.0 software (Waters) was used to select the 
considered peptides. Only the peptides present in at least four samples out of five 
were considered for the analysis. 
 
3.4.4.2 Protein deuteration 
54 pmol of protein was diluted in PBS deuterated buffer (excess of deuterium 
90%). The labeling exchange was monitored at 6 different time points: 30 s, 5 
min, 10 min, 30 min, 24 h. The labeling reaction was quenched either with 7 M 
Urea, 0.8 M TCEP, 0.4 M guanidinium chloride pH 2.4 or 2 M guanidinium 
chloride at pH 2.4 depending on the proteins immediately frozen in liquid nitrogen 
and stored in dry ice. Labelled proteins were thawed rapidly to 0 ºC and injected 
into the Synapt_G2 mass spectrometry system, where the AQUITY UPLC BEH 
C18 reverse phase column, 1.7 μm, 1.0x100 mm (Waters) and associated tubing 
were kept to 0 ºC to limit the back exchange. The Dynamix 3.0 software was used 
for the subsequent analysis of the labelled peptides.  
 
 
3.5 Vaccine Formulation and Immunoassay 
 
3.5.1 Immunization schedule 
Formulations were made using PBS and isotonic saline solution, under sterile 
wood. All the formulation had a pH range of 7.4 ± 0.5 and an osmolarity of 300 ± 
60 mOsm/Kg. When allum phosphate was added as adjuvant to the formulations 
the pH range was kept to 6.5 ± 0.5 and the osmolarity to 300 ± 60 mOsm/Kg. 
Proteins have been administered to mice in 5 µg protein content for dose; 
Glycoconjugates with laminarin were administered to mice in 5 µg for dose in 
polysaccharide content. 
Balb/c mice female were immunized subcutaneously at day 1, 14 and 28. 
Bleeding was performed at day 0 (pre-immune) day 28 (post2) and day 42 
(post3). 
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All animal studies were carried out in compliance with the arrive guidelines, the 
current Italian legislation about the care and use of animals in experimentation 
(Legislative Decree 116/92), and with the GSK Animal Welfare Policy and 
Standards. Protocols were approved by the Italian Ministry of Health 
(authorization 249/2011-B). 
 
3.5.2 Antibody titer determination by ELISA assay 
The Antibody response induced by protein carriers and glycoconjugates were 
measured by ELISA. The coating was done overnight at 4 °C on Maxisorp plates 
by adding 100 μL/well of either protein or polysaccharide. Coating for the proteins 
was done using 2 μg/mL protein solution in PBS buffer at pH 7.2. Instead for the 
polysaccharide coating, was performed at 50 μg/mL in 0.05 M sodium carbonate 
buffer at pH 9.6. The coating solution was removed by three washes with PBS 
buffer containing 0.05% of tween 20 (TPBS) (Sigma-Aldrich). A blocking step was 
then performed using adding a 100 μL/well solution of 3% (w/v) BSA in TPBS and 
incubating the plates at 37 °C for 1 h. The blocking solution was then removed by 
washing three times the plates with TPBS. 200 μL of pre-diluted serum (diluted in 
TPBS containing 0.3% (w/v) of BSA) is added on the first well of each column 
while on the others wells 100 μL of TPBS 0.3% (w/v) BSA was dispensed. A 2-
fold dilution on each well was performed transferring 100 μL of sera solution from 
well to well. The plates were incubated for 2 h at 37 °C. After incubation the 
solutions were removed and the plates were washed three times with TPBS, and 
a secondary alkaline phosphate conjugate antibodies (antimouse IgG 1:1000) in 
100 µL TPBS containing 0.3% (w/v) BSA solutions is added for 1 h at 37°C. After 
three washes with TPBS 100 µL /well 0.5 M diethanolammine buffer pH 9.6 
supplemented with 1 mg/mL para-Nitrophenylphosphate (p-NPP) (Sigma-Aldrich) 
was added and the plates were incubated at room temperature for 30 min and 
then read at 405 nm by using plate reader Biorad. Raw data were acquired with 
Microplate Software (BioRad). Sera titers were expressed as the reciprocal of 
sera dilution corresponding to a cut-off Ottical density (OD) of 1 in the case of 
carrier protein IgG titer determination or OD = 0.2 in the case of polysaccharide 
IgG titer determination. The immunization group was represented with the 
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geometrical mean of the single mouse titer with a confidential interval of 95%. The 
graphical analysis was done using GraphPad Prism 6.0 software. 
 
 
3.6 Bioinformatic analysis for MHC-II prediction 
 
The prediction analysis was performed using the IEDB analysis source.  The 
tested proteins were analyzed applying both the Consensus method(63) 
(SMM/NN) and the SMM-align methods64.. 
 
3.7 Colorimetric assays for the determination of proteins 
concentration and oligosaccharides activation  
 
During the purification process, protein content was determined by Bradford 
colorimetric assay. In the conjugates, it was determined by BCA protein assay59.  
Amino groups were determined by colorimetric assay60.  
Active ester groups, introduced in the oligosaccharides, were determined by the 
analysis of released N-hydroxy-succinimido groups61. 
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4. Results 
 
As extensively reviewed in the introductive section, several factors are important 
to determine the ability of a protein to function as a carrier. The main role of the 
carrier in glycoconjugate vaccines is thought to provide T-cell epitopes, which 
bind to the class II MHC. In the specific case of glycoconjugate vaccines, 
understanding the role of presenting peptides as well as the impact on the carrier 
efficacies, when potential MHC-II peptide binders are glycoconjugated, is 
fundamental for the selection of efficient new protein carriers and for the rational 
design of conjugation strategies. 
 
 
4.1 Selection of carrier proteins for the study 
 
4.1.1 Efficacy of the protein carriers previously tested to produce IgG anti-
saccharide 
In order to draw a working hypothesis, concerning on the importance of the MHC 
presenting peptides and their glycosylation, we analyzed the efficacy, in term of 
production of IgG anti-saccharide, of a set of 27 different carrier proteins reported 
in Tontini et al., as a function of the affinity of the predicted MHC-II binder 
peptides. The investigated carrier proteins derived from different bacteria: extra-
intestinal pathogenic E.coli (ExPEC), N. meningitidis serogroup B, group A 
Streptococcus (GAS), group B Streptococcus (GBS), and S. pneumoniae (spr); 
while the sugar antigens used for the conjugation to these carriers was laminarin. 
These proteins were selected on the basis of an absence of expected toxicity 
considering the available information: solubility in physiological buffers at 
concentrations 0.3 - 5.0 mg/mL; presence of a sufficient number of lysines for 
conjugation and molecular weight between 40 and 100 kDa. These were all 
conjugated with modified laminarin at the end reducing group. The succinimido 
diester of adipic acid (SIDEA) was used as linker to have a terminal succinimido 
ester group available to react with the primary amine group of lysine residues on 
the proteins. All the conjugates were tested in mice without the use of adjuvant in 
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order to highlight the intrinsic value of the carriers only. CRM197–Lam was used in 
each immunogenicity study as benchmark. As determined by ELISA, 15 of the 27 
conjugates did not induce anti-Lam antibody titers or induce them to a level of 5 
time inferiors49.   
 
4.1.2 MHC-II binding prediction of the 27 carrier proteins studied 
Access to bioinformatics analytic tools and curated databases on immune 
reactions and specific pathogens have been becoming more frequently crucial for 
the discovery of epitopes and the vaccine design. Currently, the Immune Epitope 
Database and Analysis Resource is the most common and used bioinformatics 
tools due to its freely availability on the IEDB website (http://www.iedb.org//). It 
includes several practical tools and methods to analyze and forecast epitopes, but 
also a broad amount of immune epitopes experimentally measured. For instance, 
the IEDB analysis resource software was applied for a direct prediction of the 
peptides presented to the MHC-II of all the carrier proteins analyzed in the study 
of Tontini et al. Since the 27 carrier proteins were tested on the Balb/c mice; the 
specific haplotype of interest, H2-IAd was used for the prediction. According to 
the peer-reviewed scientific literature, new available data and information are 
periodically used to update the database. Particularly, the last update reports has 
showed a number over 18940 of curated references, a database containing over 
424000 epitopes and over 1500000 B cell, T cell, MHC binding, and MHC ligand 
elution assays (positive and negative)62.  
The software, directly available on the IEDB website at the following 
url:http://tools.iedb.org/mhcii, allows comparing the predicted affinity of every 
peptide with that of a greater sample randomly selected. It calculates the 
percentile rank by using various available prediction methods including, 
Consensus63-64, netMHCIIpan65, SMM-align, Sturniolo, and NN-align66.  
In this study we tested proteins using the SMM-align method67, which parsed the 
input protein sequences into a series of 15-mers that overlap by 10 residues, and 
submited these series instead of the entire protein sequence. With an overlap of 
10 amino acids it was possible to capture the minimal number of 15-mers with all 
possible 9-mers binding cores with at least one flanking residues (PFRs) on both 
sides and predicts the binding affinity for each peptide. The results of these 
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analyses were provided as a nominal SMM-align rank (nominal value) and a 
prediction SMM-align (IC50 nM). Briefly the lower is the SMM-align rank, the 
higher is the binding interaction with the MHC-II. The SMM-align method predicts 
the IC50 of the peptide MHC binding affinity values, making it suitable for rational 
epitope discovery67. As guide, we considered a good and medium affinity for the 
predicted peptide ≤1000 nM68. 
 As examples of the outcome of the software, Figure 4 shows the predictions for 
the proteins CRM197 (see panel a), spr96/2021(see panel b) and GNA2091-fHbp 
(see panel c). For a better visualization, the data in the figure are shown as 
reciprocal of the nominal percentile rank, where the higher is the value, the 
stronger is the affinity for the specific MHC-II haplotype. The CRM197 protein 
showed a high affinity for the MHC-II, displaying IC50 between 539 nM and 615 
nM for the three peptides with high SMM-align rank. The spr96/2021 (see panel 
b) exhibited stronger binder affinity of predicted peptides compared to the CRM197 
protein and it had a high affinity with a low IC50 (see panel b).The GNA2091-
fHbp (see panel c) had a lower number of predicted MHC-II binders compared to 
the CRM197, and spr96/2021, having only few peptides with an IC50 lower than 
1000 nM. 
Because the side chain of lysine residues consisted in the site of conjugation, a 
specification were needed: in the case of CRM197 the predicted epitopes did not 
present any lysine residues in their sequences, while spr96/2021 and GNA2091-
fHbp, contained lysine residues. It is remarkable to stress it out considering that 
the MHC-II presentation could be influenced by the poly/oligosaccharide 
conjugation.   
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Figure 4 - Examples of SMM-align predictions: CRM197 (panel a), spr96/202 (panel b), 
GNA2091-fHbp (panel c) data prediction are shown as reciprocal of the nominal 
percentile rank (y axis), while the x axis represents the amino acid composition starting 
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from the N-terminus of the proteins. In each panel is also displayed the SMM align rank 
and IC50(nM) for the most highly affinity predicted peptides of the three proteins. 
4.1.3 Predicted MHC-II peptide affinities as a function of carrier efficiencies 
The emitted working hypothesis was very simple. We wondered if a read-out as 
macroscopic and easy that the measurement of IgG amount could reflect a 
process as complex as the binding, internalization, processing, presentation on 
MHC-II and creation of the synapse with the T-cell receptor. For this task, the 
anti-laminarin IgG titer, for each glycoconjugate, was plotted as the affinity-value 
of the carrier peptide with the highest affinity (Figure 5). We arbitrary defined a 
protein as an efficient carrier whether the anti-laminarin IgG was equal or superior 
to 1/5 of the anti-laminarin IgG produced by the benchmark CRM197, and 
according to the recommendation of the IEDB, we selected as high-affinity 
peptide those with a 1/SMM-align rank of 8, i.e. a value equivalent to IC50 not 
higher than 1000 nM. Based on the threshold used, four groups of carriers have 
been identified: 
I. Eleven carrier proteins able to induce high anti-Lam IgG titers that we 
arbitrary defined as superior or equal at 1/5 of the anti-Lam IgG titers 
induced by CRM197 contain at least one predicted high affinity MHC-II 
peptide (Figure 5, group a). 
This group indicated a potential correlation between the presence of at 
least one high MHC-II affinity peptide and a high efficacy of the protein as 
glyco-carrier. It is also interesting to notice that, with the exception of the 
two fusion proteins RrgB III-II-I and RrgB I-II-III, the spr2021 (alone or 
fused with the protein spr0096), and the GNA2091-fHbp, all the other 
carriers of this group did not contain lysine residues so as to indicate that 
the conjugation should not influence the binding of the predicted peptides. 
The protein spr2021was particularly interesting because it could function 
as an efficient or even highly efficient carrier. 
  
II. Six carriers, unable to induce high IgG titers, contained only low affinity 
predicted MHC-II peptides (Figure 5, group c). 
As for the previous group, this observation evidenceed a potential 
correlation between the presence/absence of high affinity MHC-II peptides 
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and level of IgG titers. In this particular group, the absence of predicted 
MHC-II peptides resulted in the incapability of the carrier to induce anti-
saccharide IgG.  
 
III. Seven carrier proteins, unable to induce high IgG titer, contained high 
affinity predicted MHC-II peptides (Figure 5, group b). 
At priory, this set of protein carriers did not fit with a model of “prediction of 
high affinity MHC-II peptide correlated with high efficacy of the carrier 
protein”. Specifically all those carrier predicted MHC-II peptides, except 
one, contained high affinity predicted peptides carrying lysine residues, to 
indicate the importance of lysines and their potential state of conjugation in 
the immune response.  
 
IV. Two carrier proteins able to induce high IgG titer contained low affinity 
predicted MHC-II peptides (Figure 5, group d).  
These two carriers did not fit with the model and might represent an error 
in the prediction of the MHC-II binder peptides  
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Figure 5 - The Y axis is the reciprocal of the SMM rank of the carrier peptide with the 
highest affinity (the higher the value is, the stronger the MHC-II prediction binding is); the 
X axis is the anti laminarin IgG titer normalized by CRM197 which is used as benchmark 
The vertical dashed line represents the separation between efficient (superior to) and 
non-efficient (inferior to) carriers. The horizontal dashed line represents the separation 
between high and low affinity peptides. Each dot represents a different protein. The 
CRM197 is represented in green, while in blue and yellow respectively the proteins 
containing high affinity predicted peptides with and without lysine residues. In grey the 
proteins with low immune affinity and Immune response, in red the proteins that do not fit 
the model 
 
4.1.4 Elaboration of a working hypothesis and design of the study 
The following observations allowed drawing a working hypothesis:  
1. The software of prediction applied in this analysis allowed the hypothesis 
of correlation between presence on the carrier proteins of a high affinity 
MHC-II binder peptides and IgG production efficacy could be evidenced.  
31 
2. The MHC-II peptide prediction allowed speculating that 
conjugated/unconjugated lysine residues in the predicted MHC-II peptides 
may drive the production of IgG. 
3. The production of IgG seemed to be driven by the peptides of the highest 
affinity. 
4. The fact that a correlation between predicted MHC-II peptides and carrier 
efficacy could be established implied that glycoconjugates were efficiently 
internalized and processed. These steps were not limited and only the 
MHC-II association was monitored.  
To test these hypotheses, the protein spr96/2021 was selected as a carrier 
model. The spr96/2021 exhibited stronger binder affinity predicted peptides 
compared to the CRM197 protein (Figure 4). In fact CRM197 had SMM-align 
affinity IC50 of 539 nM with peptides not containing lysine residues. Whereas 
spr96/2021 showed a SMM-align affinity IC50 of 373 nM and 399 nM for the 
two peptides with the strongest affinity, which contained three lysine residues. 
Regarding the efficacy of the proteins as carrier, the conjugate spr96/2021 
induced an anti-Lam antibody titer significantly higher than the one induced by 
CRM197–Lam (Figure 5). Spr96/2021 is a recombinant fusion of the two 
pneumococcal proteins: spr0096 (LysM domain secreted protein) and spr2021 
(secreted PcsB protein)69,70,71. To address the question whether one of the two 
moieties could be responsible for this strong carrier effect, Lam conjugates 
with spr0096 and spr2021 respectively, were tested in mice. No response was 
induced by the spr0096 conjugate and very low by the spr2021 one, indicating 
that some feature derived from the fusion of the two proteins was critical for 
the carrier activity. The planed acitivities were: 
 Include the fusion protein spr2021/96 
 Empirically determine if the predicted MHC-II peptides bind the MHC-II 
complex 
 Evaluate the immunogenicity of the carrier proteins 
 Evaluate a relationship between carrier protein and pattern of 
glycosylation.  
 Generation of mutant constructs based on the evaluation of different 
pattern of glycosylation in the protein carriers. 
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4.2 Evaluation of the S. pneumoniae spr96/2021, 2021, 2021/96 
proteins immunogenicity in mice 
 
To evaluate the ability of the S. pneumoniae carriers spr96/2021, 2021, 2021/96 
at generating an immune response, the proteins (5 µg) were used to immunize 
mice. The study was performed with and without the presence of alum adjuvant 
and CRM197 was used as positive control. The anti-protein antibodies IgG titers 
were evaluated after the third immunization. All the S. pneumoniae proteins 
tested showed a significant higher IgG titers than the one induced by the CRM197 
(as shown in Figure 6). The protein spr2021 alone or in fusion with the spr0096 as 
spr96/2021 or 2021/96 were highly immunogenic in mice showing a high IgG titer 
(GMT value) without the use of adjuvant, compared to the IgG titer for the 
CRM197. The GMT value obtained for the spr96/2021, 2021/96 and 2021 were 
respectively 5290, 8947, 2706, while the one obtained for the CRM197 was 31. 
The three forms of the proteins spr2021 were able to produce a similar 
immunological response, indicating that without any modification of the lysine 
residues, the three proteins were highly immunogenic. We also attempted to 
correlate the efficacy in the production of IgG to the affinities to the predicted 
MHC-II peptides (370 nM for spr2021 and 548 nM for CRM197, Figure 4), 
although it could not be excluded that other factors such as the binding, the 
internalization and the processing could affect the immunogenicity of the proteins. 
Indeed, alum may exert its role as a delivery system to immune cells directly 
being engulfed by immune cells within the draining lymph nodes72, supporting the 
internalization of the antigen protein. In fact the CRM197 protein in presence of 
Aluminium phosphate had a significant increase in its immunogenicity. It had a 
GMT IgG titer value of 10773 in presence of Alum while a GMT of only 31 when 
administered without it. It could be speculated that even if the CRM197 had high 
immunogenic predicted peptide, its ability to generate an immune response could 
be affected by the internalization and processing. Instead the proteins spr2021, 
spr96/2021 and 2021/96 in presence of alum adjuvant did not show a substantial 
increase in immunogenicity (Figure 6). The following step of the study was to 
identify the lysine residues involved in the conjugation, for doing this the spr2021, 
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the fusions spr96/2021 and 2021/96 were conjugated with the Laminarin 
polysaccharide. 
 
 
 
 
Figure 6 - Anti-protein IgG response induced by spr2021, spr96/2021 or spr2021/96 without and 
in presence of adjuvant, compared with the CRM197 used as positive control.  
Anti-carrier IgG represented by each dot indicates a single mouse ELISA titer; the horizontal 
bar(red) represents the GMT of the group, instead the vertical bar shows the statistical 95% CI.  
 
4.3 Conjugates preparation of laminarin glycoconjugates 
spr96/2021, spr2021 and spr2021/96 
 
The Laminarin glycoconjugates were generated by chemical derivatization at the 
reducing end of the polysaccharide with an adipic acid linker (succinimido diester 
of adipic acid) as described in the materials and methods section. The activated 
polysaccharide was reacted with the different protein carriers using the same 
activated polysaccharide/protein molar ratio.  
Figure 7 reports a schematic description of the chemical reactions to produce the 
laminarin conjugates.  
34 
 
 
The conjugates spr96/2021, 2021, and 2021/96 were analyzed by SDS-PAGE 
electrophoresis to control the efficacy of the reaction (Figure 8). Figure 8 overleaf 
shows the classical smear of glycoconjugates due to variable sugar chains bound 
to the protein, and the band corresponding to the starting recombinant protein is 
not anymore visible to indicate a complete conjugation of the carrier.  
As described in chapter 2 – Material and methods, the glycoconjugates were 
purified from the unreacted polysaccharide and the glycosylation degree was 
calculated in term of total saccharide and free saccharide (not conjugated). The 
glycosylation degree for protein was between 0.22 and 0.36 in term of 
saccharide/protein ratio (w/w); the content in free saccharide was quite 
 
Figure 7: Schematic reaction of Laminarin glycoconjugates formation  
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homogenous between 9.2 and 12.1 % (Table 2), in agreement with the previously 
published data(49). 
 
Figure 8: SDS-page of spr96/2021, 2021, and 2021/96 proteins (respectively a, b, c) and their 
relative laminarin glycoconjugates(a1, b1, c1).  
 
Laminarin conjugates 
 
Total Saccharide 
µg/mL 
Saccharide/protein 
(w/w) 
Free 
saccharide 
% 
Spr2021  550.9 0.36 11.1 
Spr96/2021  412.9 0.22 12.1 
Spr2021/96  541.5 0.29 9.2 
Table 2: Free saccharide and saccharide/protein (w/w) ratio determination in Laminarin 
glycoconjugates. 
 
4.4 Immune response evaluation of the S.pneumoniae 
spr96/2021, 2021/96, 2021 Laminarin conjugates 
 
The S.pneumoniae laminarin conjugates generated were tested in mice and the 
anti laminarin response was evaluated monitoring the antilam IgG titer by ELISA 
assay. The CRM197-Lam conjugate was used as control.  The study was 
performed without adjuvant with an immunization dose of 5 μg in term of 
saccharide. The anti-laminarin antibodies IgG titers were evaluated after the third 
immunization. Regarding the efficacy of the conjugate spr96/2021 the anti-
laminarin IgG titer (Figure 9) was significantly higher than the one induced by 
36 
CRM197-Lam as previously described (p value =0.0023). It was also confirmed 
that the spr2021-Lam had a lower immunogenicity when compared to the fused 
conjugate spr96/2021-Lam (p value=0.007). Interestingly, the fused conjugate 
spr2021/96-Lam showed a lower immune response compared to the spr96-2021-
Lam (p value=0.0011). These results accentuated the possibility that some 
features derived from the fusions were critical for the glycoconjugates activity. A 
different rearrangement in the two fused protein structures and the possible 
different glycosylation pattern in the conjugates may drive to a different immune 
response.  
 
 
 
Figure 9: Anti-polysaccharide IgG antibody titer induced by Laminarn conjugates in S. 
pneumoniae conjugates, CRM197–Lam is used as benchmark. Each spot indicates a single mouse 
ELISA titer, the horizontal red bar refers to the GMT of the group and the vertical bar shows the 
95% CI. Non parametric Mann–Whitney test has been used for p value calculation. 
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4.5 Determination of glycosylation factors in S. pneumoniae 
constructs 
 
Because differences in term of immunogenicity against the polysaccharide 
antigen were identified for the three different carrier constructs spr96/2021, 
spr2021 and spr2021/96, we tried to identify features in the protein structures and 
glycosylation in the conjugates that could lead to a different immune response. 
Two approaches were used:  
a. Determination of the glycosylation pattern. 
b. Determination of differences in the dynamics of the proteins leading to a 
different glycosylation.  
 
4.5.1 Pattern of glycosylation for the spr2021, spr96/2021 and spr2021/96 
conjugates 
The different glycoconjugates were analyzed to identify possible differences in the 
glycans distribution especially regarding the lysine residues present in the 
predicted MHC-II peptide binder. Chemical deglycosylation method and Mass 
Spectrometry techniques were combined to identify the glycosylation sites. We 
took advantages of the differences between the glycosidic bonds and the covalent 
linking of the glycan to the protein. To be more specific, the amide bond of the 
protein-SIDEA-Sugar and the glycosidic bond of the rest of the oligosaccharide 
are very different from the chemistry point of view (Figure10). After the chemical 
deglycosylation process, only the SIDEA-monosaccharide was retained on the 
glycosylated lysines allowing to distinguish between glycosylated/unglycosylated 
lysine residues by mass spectrometry. 
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Figure 10 - (a) Different chemical effect of TFMS treatment on glycosidic bond and N-linkage of 
reduced glycan bound to SIDEA. (b) Principal of the glycosylation method coupled with MS 
analysis. 
 
4.5.2 Chemical deglycosylation 
The chemical deglycosylation was performed by chemical solvolysis as described 
in section 3. The deglycosylation procedure removed all sugars that contained 
covalently bound sugar chains. Amide bonds were stable to TFMS and so the 
integrity of the protein was maintained. After the deglycosylation of the 
conjugates, sugars were removed and only the SIDEA-monosaccharide linked to 
the side chains of lysine residues remained. This adduct served as label for the 
identification of conjugated lysines .  
The integrity of the proteins after the deglycosyation were checked by SDS-PAGE 
(Figure 11). The characteristic smear of the glycoconjugates was not anymore 
present after the chemical reaction and to assess that the carriers did not show 
evident degradations due to the harsh deglycosylation reaction, the starting 
recombinant proteins were also loaded on the SDS-PAGE gel. No difference in 
the apparent molecular weight of the carriers and the deglycosylated carriers 
were observed.  
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Figure 11 - Deglycosylated fractions analyzed by SDS-PAGE the single band characteristic of the 
spr96/2021, spr2021 and 2021/96 proteins is shown after the treatment with TFMS on the 
glycoconjugates confirming the removal of the sugar. 
 
 4.5.3 Glycosylation pattern identified by mass spectrometry 
Almost all currently marketed glycoconjugate vaccines contains large and 
heterogeneous glycans, conjugated by different methods, to the carrier proteins 
(Section 1.3). Many parameters such as length of the glycan, incorporation into 
the protein, conjugation linker and the distance from the protein can influence the 
immunogenicity of the vaccine conjugate73,74. Although the correct arrangements 
of the polysaccharide antigens make it available to interact with the APCs, the 
attachment site of the carbohydrates to the carrier protein can also be crucial for 
the induction of a T-cell response75,44. Most of the glycoconjugate in clinical use 
are prepared by covalent linkage of the carbohydrate to the side chain of lysine. 
This conjugation generally is considered highly random, and hard to control, also 
inducing batch-to-batch variability in the immunological properties of the vaccine. 
Analysis and localization of the glycosylation sites on conjugate vaccines are very 
important for the understanding of their mechanism of action76. The identification 
of the lysine residues involved in conjugation has only recently started to be 
explored76,77. Different groups have studied the possible conjugation on the 
common carrier protein CRM197, demonstrating that the conjugation reaction take 
place with preferences for particular sites lysine residues. Crotti et al. and more 
recently Möginger et al., identified that not all the lysine residues are equally 
reactive and prone to the conjugation. It has been demonstrated that the steric 
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accessibility, the local amino acid environment and the protein secondary 
structure are the most relevant parameters; influencing the conjugation reaction 
under not-denaturating conditions.  
 
Considering all these aspects, we identified which were the most abundant 
glycosylation on the three different conjugates. The approach used in this study 
had the advantage to easily determine the glycosylation sites obtaining intact 
proteins tagged on the conjugated lysine residues, minimizing the problem related 
to hindrance of the polysaccharide that can reduce the efficacy of the trypsin 
proteolitic enzyme used for the digestion. 
The deglycosylated carriers were analyzed by LC-MS/MS analysis after tryptic 
digestion performed as described in section 3. The peptides and glycopeptides 
identification was carried out from the generated peak list using Mascot engine 
software or the peaksoftware adding the modifications of SIDEA-Glc(+291.13180 
Da) corresponding to the modification due to the presence on the side chain of 
lysine of SIDEA- glucose (SIDEA-Glc) leftover from the deglycosylation. To 
assign glycosylation side localization, we only considered the peptides in which, 
the modified peptide, was shown in MS/MS spectra as fragment ion displaying the 
b and/or y fragments of the modified lysines (Figure 12).   
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Figure 12 - example of tandem mass spectrum of the identified glycopeptides 
(R.QAELK
#
AAELSLAAEK.A; R.AAAVAEAAYK
#
EK
#
R.A ) from protein spr2021 and spr2021/96. In 
red on the sequences are highlighted the b and y transitions carrying the modified lysines.   
 
Besides the results obtained using the MS/MS ion search, for increasing the 
identification of the unmatched spectra and monitored potential uncharacterized 
modifications on the modified lysine residues, the Mascot Error Tolerant 
Search was used, or the de novo sequencing function in peaks software was 
used. These tools allowed increasing the coverage of the proteins and identifying 
other modifications on the lysine residues. In particular, three other modifications 
were highly recurrent: +128.1075 Da associated to the modification of the lysine 
residues with the SIDEA linker, +218.1671 Da and +100.0160 Da. It was not 
possible to define these unknown modifications. These modifications probably 
derived from a rearrangement of the glycan structure after the treatment of 
solvolysis.  
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The Table 3 below lists some of the glycosylation that were identified in this work 
for the S. pneumoniae protein carriers. It is interesting to notice that the peptides 
predicted to have the highest affinity for the MHC-II complex also presented a 
different pattern of glycosylation. In particular, we identified that the peptides 
AAAVAEAAYKEKR and QAELKAAELSLAAEK were found mainly glycosylated in 
spr2021 and spr2021/96, while these modified peptides were not identified in 
spr96/2021 according to the stringent conditions we applied to the identification of 
modified peptides (Figure 13). 
 
Conjugate Sites Ion score Peptide sequence# 
Spr2021-Lam 245 93.4 R.AAAVAEAAYK#EKR.A 
 245, 247 79 R.AAAVAEAAYK#EK#R.A 
203 102.1 K.QAELK#AAELSLAAEK.A 
    
    
Spr2021/96-Lam 213, 215 80.8 R.AAAVAEAAYK#EK#R.A 
 171 66.7 K.QAELK#AAELSLAAEK.A 
 
Table 3 - Example of peptides presenting lysine residues glycosylated (#) in spr2021-Lam, and 
spr2021/96-Lam. 
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Figure 13 - Glycosylation pattern for spr96/2021 and 2021/96: In red are marked the 
glycosylated lysine in the two fusion proteins. In violet and yellow are highlighted the peptides with 
highest affinity for the predicted MHC-II peptides. 
 
4.5.4 HDX-MS analysis on spr2021, spr96/2021 and spr2021/96 carrier 
proteins for structural differences 
After the identification of a different pattern of glycosylation for the three different 
constructs we tried to better characterize the factors that could have lead to a 
different glycosylation. Due to differences in the steric interactions among the 
three constructs, the lysine residues could not be equally accessible for 
conjugation resulting in a different pattern of glycosylation. The spr2021 alone or 
in the two fusions were analyzed by Hydrogen deuterium exchange (HDX) 
technique with on-line pepsin proteolysis digestion, to evaluate the possible 
differences in conformation and dynamics structure among the proteins. 
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The rate of backbone amide hydrogen exchange in solution is directly dependent 
on the structure and dynamics of the protein. Therefore regions not exposed will 
exchange more slowly than regions fully exposed to the solvent.  
The spr96/2021 was used for the pepsin peptide map, to generate a full map 
covering the full length of the protein in order to monitor the deuterium uptake in 
the entire sequences of spr2021, 96/2021, 2021/96. The peptides were assigned 
to the sequence according to their fragmentation in MS/MS. nº of 65 peptides 
were identified in at least 4 of 5 repeated analysis and represented a coverage of 
85%. The HDX-MS analysis was performed at 6 deuteration points (30 s, 5min, 
10min, 30min, 1 h and 24 h). When the experiment was performed at room 
temperature, no significant differences in incorporation were verified for the three 
S. pneumoniae proteins (data not shown). A difference in the incorporation was 
instead identified at 0 °C when the dynamics of the protein is slowed down. 
Figure 14 illustrates the difference index of incorporation between the spr96/2021 
and the spr2021/96. The data are plotted as the difference in relative uptake of 
each peptide (dots) in the selected state (lines). The closer the dots and lines are 
to the zero, the lower is the difference (in term of incorporation) between the 
proteins compared. 1 Da of difference in the incorporation was used as threshold 
to define a difference considered to be significant. Differences in the dynamics of 
the proteins were pointed out on the spr0096 region comparing the fusion 
proteins spr96/2021 and 2021/96 with a maximum difference of incorporation of 5 
Da when the analysis was performed a 0 °C. The peptides in the C terminus path 
of the spr0096 region in the fusion of spr96/2021 present a faster kinetics of 
labeling due to a more accessible structure compared to the spr2021/96; however 
this difference was displayed only when the analysis was performed at 0ºC, when 
the dynamic of the proteins was reduced. 
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Figure 14 - Difference index of incorporation for the protein spr96/2021 and spr2021/96 each dot 
represents a peptide and each line represents a different state of deuteration. In the green box is 
represented the difference in the incorporation for the spr0096 in the two fusion proteins. In the 
blue box the difference in the incorporation for the spr2021. 
 
Focusing our attention on the spr2021region of the proteins, that was the one 
carrying the predicted MHC-II peptides found differently glycosylated in the three 
constructs, we observed that the proteins appear at highly dynamics, displaying a 
high level of deuterium incorporation. Figure 15 panel a shows the deuterium 
incorporation for the protein spr2021. Briefly, each line represents a different time 
point and each dot represents a peptide. The lower is the uptake of deuterium, 
the closer are the line and dot to the zero. A lower incorporation is related to a 
more structured region, in which the peptide is not accessible to the solvent and 
viceversa.  
We distinguished among high, medium and low dynamics of the peptides 
considering a high incorporation≥40%, 15%≤medium≤40%, low≤15% respectively 
in term of relative uptake. When the experiment was performed at room 
temperature, almost all the spr2021 protein showed a relative incorporation higher 
than 40% (data not reported). The analysis performed a 0 °C, allowed to better 
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characterize the protein structure, and in the identification of regions with a lower 
incorporation. At this temperature, the uptake of deuterium was slowed down in 
the regions more prone to interact. This aspect was in agreement with the 
crystallography structure available for the spr2021 protein78.  
In Figure 15 panel b the crystal structure of the spr2021 is shown and compared 
to the relative uptake of deuterium for each region identified. The region with high, 
medium, and low incorporation assigned in the relative uptake Figure 15 in panel 
a (indicated as A, B, C) are highlighted to the crystallography structure in panel b. 
In blue and green on the crystallography structure are showed the regions with an 
incorporation of deuterium ≤15% (blue) and between 15 and 40% (in green) are 
reported. The interhelix interactions in the coil-coil domain, mainly mediated by 
hydrophobic interactions and hydrogen bonds, leads to a lower incorporation.  
The C-terminus domain presented β-sheet with a robust network of hydrogen-
bond interactions also leading to a more structured region in agreement with the 
lower deuterium incorporation. The high dynamic of the proteins did not allow 
identifying differences, in term of protein structure that could help the 
understanding of the different pattern of glycosylation among the three constructs. 
As described, the spr2021 showed a similar incorporation among the three 
constructs (Figure 14).The proteins were highly dynamics and it was not possible 
to define a correlation between differences in the pattern of glycosylation and the 
deuterium exchange. However, it could be observed, comparing the pattern of 
glycosylation and the structure analysis performed by HDX that, in all the three 
constructs the lysines involved in the conjugation were presented on the more 
dynamic regions of the proteins. Lysines presented in the interhelix interaction in 
the coil-coil domains, and the C terminus region highlighted in blue and green on 
the crystallography structure (Figure 15 panel b), were found not glycosylated. In 
agreement with the possibility that lysines more exposed to the solvent were also 
more likely glycosylated.  
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Figure 15 - Dynamics of the spr2021 at 0°C. In panel a is shown the relative uptake for the 
protein spr2021, each dot represents a peptide and each line represents a different state of 
deuteration. Incorporation: high ≥40%, 15%≤medium≤40%, low≤15%. Each region with high , 
medium, and low incorporation assigned in the relative uptake figure in panel a (indicated as A, B, 
C) are assigned to the crystallography structure in panel b highlighted in red (high incorporation, 
green(medium), and blue(low). 
 
 
4.6 Generation of proteins mutant and laminarin glycoconjugates 
 
Differences in the pattern of glycosylation were identified for the three carrier 
proteins spr96/2021, 2021 and 2021/96. The two peptides predicted to have the 
highest affinity for the MHC-II complex presented different pattern of glycosylation 
(Figure 13). The peptides AAAVAEAAYKEKR and QAELKAAELSLAAEK were 
found mainly glycosylated in spr2021 and spr2021/96, the two constructs with the 
lower immunogenicity against the polysaccharide antigen. These modified lysines 
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were not identified in spr96/2021, the carrier protein that leads to a higher 
immunogenicity against laminarin. Based on correlation that predicted MHC-II 
peptides were mainly glycosylated on the proteins that raise a lower anti-laminarin 
IgG titer, we speculated that the glycosylation on the presented MHC-II peptide 
could affect the MHC-II CD4+T cells  interaction and so the immune memory 
against the polysaccharide antigen. For evaluating the rule played by the 
glycosylation on the MHC-II predicted peptides two strategies were used. The first 
strategy considered: 
I. Generating a series of mutants for the spr2021 and 2021/96 protein in 
which the lysines residues on the predicted MHC-II peptides 
AAAVAEAAYKEKR and QAELKAAELSLAAEK were substituted with an 
Arginine residue. In this way it can be possible to prevent the glycosylation 
on the specific site and evaluate the rule played by these peptides.  
II. Insertion of the MHC-II predicted peptide from the CRM197 protein 
IALSSLMVAQAIPLV as linker between the spr2021 and spr0096 proteins. 
As a second strategy we selected another carrier protein, the GNA2091-fHbp 
previously analyzed in term of immune response against laminarin antigen. This 
glycoconjugate displayed a low immune response compared to the CRM197 
conjugates used as control. The GNA2091-fHbp showed in is structure low affinity 
MHC-II predicted peptides (IC50 772 nM) also containing lysine residues (see 
Figure 4). We produced mutants of this protein in which the linker between the 
GNA2091 and fHbp proteins were substituted with the predicted CRM MHC-II 
peptide IALSSLMVAQAIPLV and with the predicted spr2021 MHC-II peptides 
KRASQQQSVLASANT. In this last case, the lysine residues presented on the 
peptides were also substituted with Arginine residues (i.e. 
RRASQQQSVLASANT) avoiding the possible conjugation on the specific lysine 
residue. 
 
4.6.1 Proteins production and characterization 
To perform the conjugation, high pure amount of proteins was needed. 
Recombinant constructs of these proteins were produced and purified as 
described in materials and methods. The purified proteins showed a high degree 
of purity, which was verified by analytical size-exclusion high-performance liquid-
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chromatography (SEC-UPLC); this was around 90-97% among all the proteins 
produced. The SEC-UPLC chromatography of the purified spr96/2021 and 2021 
are shown in Figure16 as an example of the analysis. To verify the molecular 
weight of the proteins entire mass were performed verifying the correct molecular 
weight. The entire mass, assessed by MS, are shown in Table 4; some of the 
proteins showed N-terminal methionine excision (NME)79 with a loss of 131.1986 
Da from the theoretical molecular weight. The entire masses obtained were in 
agreement with primary sequences of the proteins produced. 
The content in lipopolysaccharide was evaluated using the endotoxin testing 
system (Charles River). When the content of endotoxins was higher than 0.05 
EU/mL, the lipopolysaccharides were removed as described in Chapter 3.  
 
 
Protein Expected Mass (Da) Obtained Mass (Da) 
spr2021  42743.16 42745.77±2.59 
Spr2021_Lys204Arg 42771.18 42772.08±0.65 
Spr2021_Lys248Arg 42771.18 42771.70±0.35 
Spr2021_Lys204Arg_Lys246Arg_Lys
248Arg 
42827.20 42827.53±0.32 
Spr2021/96  58854.37 *58727.85±1.76 
Spr2021/96_Lys172Arg 58882.38 *58750.22±3.38 
Spr2021/96_Lys216Arg 58882.38 *58753.96±1.69 
Spr2021/96_Lys172Arg_Lys216Arg 58910.39 *58778.29±3.83 
Spr2021/96_Lys172Arg_Lys214Arg_
Lys216Arg 
58938.41 *58805.56±5.79 
Spr2021-(CRM197)-96 59959.90 *59827.77±5.54 
GNA2091-fHbp 46282.00 *46149.89±2.75 
GNA2091-(2021)-fHbp 47531.66 *47401.07±2.42 
GNA2091-( CRM197)-fHbp 47622.50 *47491.13±2.97 
 
Table 4 - Entire mass of the S.pneumoniae and N. meningitidis proteins produced, the 
star (*) is indicating the loss of methionin. 
 
50 
 
Figure 16 - SEC-UPLC profile of purified spr2021(A), 2021/96_Lys172Arg(B), the absorbance 
(AU) was acquired at 280nm wavelength, the elution time for each peak is indicated in each panel. 
The peak % area indicates the % of the peak component among the total 'detectable' peaks. 
 
To further characterize possible disorders in the protein structures correlated to 
the mutations on the native sequences of the Streptococcus pneumoniae 
spr2021-96 and spr2021, and Neisseria meningitis GNA20191-fHbp, the thermal 
stability of the generated proteins was analyzed by differential scanning 
calorimetry (DSC). The same thermal stabilities for the spr2021, spr2021/96 and 
their relative mutants were verified. Two peaks corresponding to melting 
temperature transitions (Tm) at 29.96 and 52.68 ºC were showed for the 
spr2021/96 and its relative mutants (Figure 17). The same analysis was 
performed for the spr2021 and its mutants; a Tm of 29.96 and 55.02 ºC was 
showed (Figure 18). All the point mutation did not significantly affect the melting 
temperature of the proteins. Different thermal stability were instead showed for 
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the spr2021-(CRM)-96 mutant in which the linker GSGSGGG was substituted 
with the sequence GIALSSLMVAQAIPLVG corresponding to the CRM197 MHC-II 
predicted peptide. In this case the Tm1 was maintained at 30 ºC but the Tm2 was 
instead lower from 52.68°C to the initial construct to 47.68 ºC (Figure 19). The 
modification of the linker between the two proteins srp2021 and spr96 led to a 
change in the structure conformation. Same thermal stability was verified for the 
GNA2091-fHbp and its relative mutant. Two different peaks were observed at Tm1 
66 ºC and Tm2 83 ºC (Figure 20). In both the two constructs the change of the 
linker did not affect the melting temperature of the GNA2091-fHbp protein.  
 
 
 
Figure 17 - DSC profiles of spr2021/96 protein and  mutants with the relative Tm associated to 
each peak. Samples are indicated as shown in the legend. 
 
52 
 
 
Figure 18 - DSC profiles of spr2021 protein and the respective mutants with the relative Tm 
associated to each peak. Samples are colored as follow: red spr2021_Lys204Arg, green 
spr2021_Lys248Arg, blue spr2021_lys204Arg_Lys246Arg_Lys248Arg and light blue for the 
spr2021 
 
 
 
Figure 19 - DSC profiles of spr2021/96 protein and the spr2021-(CRM)-96 mutants with the 
relative Tm associated to each peak. Samples are indicated as shown in the legend. 
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Fig20: DSC profiles of GNA2091-fHbp protein and its mutants GNA2091-(2021)-fHbp, GNA2091-
(CRM)-fHbp with the relative Tm associated to each peak. Samples are indicated as showed in the 
legend. 
 
4.6.2 Immune response evaluation of S. pneumoniae and N. meningitidis 
mutated proteins in mice 
For evaluating the ability of the mutated S. pneumoniae and N. meningitidis 
produced to maintain an immune response, the mutants were tested in mice; the 
spr2021 and spr2021/96 were used as controls from which the immune response 
should be increased on the mutated proteins. Studies were performed without the 
use of adjuvants for all the proteins and mutants with an immunization dose of 5 
µg in term of total protein. The anti-protein antibodies IgG titers were evaluated 
after the third immunization (Figure 21). All the S. pneumoniae mutants tested 
showed an IgG titer that is comparable to the spr2021 and spr2021/96 proteins 
(Figure 21 panel a, b). The same behavior was showed for the N. meningitidis 
mutants when compared to the control GNA2091-fHbp (Figure 21 panel c). Non 
significant differences were obtained in term of immunogenicity for mutated 
carriers. The mutations did not significantly affect the immunogenicity of the 
carrier proteins. It was possible to speculate that the immunogenicity of the 
modifications made, did not affect the process of presentation and internalization 
of the new carriers produced.  
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Figure 21 - Anti-carrier IgG response induced by spr2021, spr2021/96 or GNA2091-fHbp proteins 
in comparison with the corresponding mutants. 
In panel (a) is shown the anti-carrier IgG response induce by mutated spr2021 without presence of 
adjuvant in comparison with the positive control spr2021.  
In panel(b) is shown the anti-carrier IgG response induce by mutated spr2021/96 without 
presence of adjuvant in comparison with the spr2021/96 original construct. 
In panel(c) is shown the anti-carrier IgG response induce by mutated GNA2091-fHbp without 
presence of adjuvant in comparison with the GNA2091-fHbp wild type. 
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4.6.3 Conjugates preparation of laminarin glycoconjugates for spr2021, 
2021/96 and GNA-fHbp wild type and mutants 
The Laminarin glycoconjugates were obtained as already described in Section 4.3 
where Figure 7 illustrates schematic description of the chemical reactions to 
obtain the laminarin conjugates. The conjugates were analyzed by SDS-PAGE 
electrophoresis to control the efficacy of the reaction. The classical smear of 
glycoconjugates due to variable sugar chains bound to the protein was observed, 
and the band corresponding to the starting recombinant protein was not any more 
visible indicating the complete conjugation of the carriers (Figure 22). The 
glycoconjugates were purified from the unreacted polysaccharide as described in 
Section 3, and the glycosylation degree was calculated in term of total saccharide 
and free saccharide (not conjugated). The saccharide content among the S. 
pneumoniae and N. meningitidis conjugates to Laminarin polysaccharide is 
reported in Table 5. The glycosylation degree for protein was between 0.19 and 
0.7 in term of saccharide/Protein ratio(w/w), the content in free saccharide was 
quite homogenous waving between 6.1 and 13.7 % for the spr2021/96 conjugates 
and between 5.3 and 6.5% for the GNA2091-fHbp proteins and mutants. 
 
 
 
Figure 22 - Examples of SDS-page for the generated conjugates: Proteins 
spr2021/96_Lys172Arg,spr2021/96__Lys172Arg_Lys214Arg_Lys216Arg,spr2021_Lys204Arg, 
and spr2021_Lys204Arg_Lys248Arg (respectively a, b, c, d) and their relative laminarin 
glycoconjugates(a1, b1, c1,d2). 
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Laminarin conjugates 
 
Total Saccharide 
µg/mL 
Saccharide/protein 
(w/w) 
Free 
saccharide 
% 
Spr2021_Lys204Arg  354.4  0.21 12.1 
Spr2021_Lys248Arg 269.7 0.61 10.0 
Spr2021_Lys204Arg_Lys246
Arg_Lys248Arg 
421.4 0.41 16.6 
Spr2021/96_Lys172Arg 465.1 0.34 10.7 
Spr2021/96_Lys216Arg 569.3 0.20 13.2 
Spr2021/96_Lys172Arg_Lys
216Arg 
491.3 0.39 6.1 
Spr2021/96_Lys172Arg_Lys
214Arg_Lys216Arg 
437.7 0.19 13.7 
Spr2021-(CRM)-96 582.1 0.35 10.9 
Spr2021/96  541.5 0.29 9.2 
GNA2091-fHbp 663.6 0.41 6.5 
GNA2091-(CRM)-fHbp 201.3 0.47 5.3 
GNA2091-(2021)-fHbp 581.5 0.7 - 
 
Table 5 - S. pneumoniae and N. meningitidis Laminarin glycoconjugates: total content of 
saccharide, free saccharide and saccharide/protein (w/w) ratio.  
 
 
4.7 Immune response evaluation of mutants Laminarin 
conjugates in mice 
 
For testing the ability of the new glycoconjugates produced to increase the 
immune response against the polysaccharide antigen, Laminarin conjugates 
spr2021, spr2021/96 and mutants were tested in mice. The study was performed 
without the use of adjuvants with an immunization dose of 5µg in term of total 
saccharide. The anti-Laminarin antibodies (IgG) were evaluated after the third 
immunization. Comparing the spr2021 conjugates and its relative mutants (Figure 
23 panel b), the point mutations made on the predicted MHC-II peptides did not 
allow a significant increase in the immunogenicity against the polysaccharide 
antigen. The same effect was showed in the case of the spr2021/96 and its 
relative mutants (Figure 23 panel a). The spr2021-CRM-96 conjugate, in which a 
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predicted MHC-II peptide from the CRM197 sequence was added to the fusion 
protein spr2021/96 also showed a similar immune response compared to the 
original construct spr2021/96-Lam. In all constructs we obtained a similar immune 
response and a non significant increase among them was identified. Regarding 
the N. meningitidis conjugates, predicted MHC-II peptide from the CRM197 protein 
and the spr2021 were added to the sequence with the aim of increasing the 
immune response of GNA2091-fHbp. Comparing the mutant tested to the original 
construct GNA2091-fHbp a non significant increase in the immunogenicity was 
observed. (Figure 23 panel c). 
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Figure 23 - Anti-laminarin IgG response induced by spr2021 spr2021/96, or GNA2091-fHbp 
conjugates in comparison with the corresponding mutants. 
In panel (a) is shown the anti-laminarin IgG response induce by mutated spr2021 without 
presence of adjuvant in comparison with the spr2021.  
In panel(b) is shown the anti-laminarin IgG response induce by mutated spr2021/96 without 
presence of adjuvant in comparison with the spr2021/06. 
In panel(c) is shown the anti-laminarin IgG response induce by mutated GNA2091-fHbp without 
presence of adjuvant in comparison with the GNA2091-fHbp. 
Anti-carrier IgG represented by each dot indicate a single mouse ELISA titer, the horizontal 
bar(red) is the geometric mean of the group, instead the vertical bar shows the statistical 95% CI. 
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5. Conclusions 
 
Currently, glycoconjugate vaccines are among the safest and most efficacious 
vaccines developed so far, however they are still not completely characterized. 
Data show that the immunogenicity of conjugate vaccines can be affected by 
many variables such as the carrier protein, the conjugation chemistry and the 
carbohydrate antigen, resulting in different immunological properties. For 
instance, several studies have been published focusing on the influence of the 
carbohydrate on the immunogenicity of glycoconjugate vaccines and suggesting 
that chain length, conjugation process, saccharide loading onto the protein could 
somehow influence the glycoconjugate immunogenicity80,81,82. While these factors 
are often stated in publications, the attention on the protein carrier as the key 
factor on vaccine profile83 has not been widely reported. The mechanism of action 
of glycoconjugate vaccines and in particular the role played by both the 
carbohydrate and the protein carrier during antigen presentation, the interaction 
with the MHC-II complex and the following interactions with the T cell receptor are 
still not completely clarified. Polysaccharides are generally considered to be T cell 
independent antigens and so not able to bind the MHC-II complex84. For this 
reason, the elicitation of T cell helpers by glycoconjugates is generally attributed 
to the peptide moieties, which is generated from the protein carrier processing. 
Avici et al. showed that carbohydrate motifs can be presented to the MHC-II 
thanks to the peptide that act as anchor for the binding to the MHC-II. In fact, the 
authors identified specific T cell clones for the specific carbohydrate antigen. A 
further consideraton is that most of the conjugate vaccines are produced from 
large poly/oligosaccharides, randomly distributed at the carrier surface, limiting 
the possibility that carbohydrate processing in the lysosome results in a sufficient 
quantity of homogenous glycopeptide suited for the T cell binding48. Aiming at 
bringing light to the influence of conjugation on processing and presentation of 
glycoconjugates, we first clustered the efficacy of 27 protein carriers reported in 
litterature49, as a function of the presence in their sequences of peptides predicted 
to bind MHC-II with high affinities, as well as the presence/absence in these 
peptides of lysine residues, the amino acid involved in the conjugation49. We were 
able to evidence that carriers that did not induce anti-Lam antibody titers or 
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induce them to a level 5 time inferiors to the CRM197-Lam used as benchmark, 
either do not bear predicted MHC-II-binder peptides of high affinity, or contain 
predicted MHC-II-binder peptides of high affinity that carry lysine residues. From 
this observation we made the hypothesis that the conjugation of the lysine 
residues present in predicted MHC-II-binder peptides of high affinity might 
considerably reduce the capability of a protein to function as an efficient carrier. 
The hypothesis was also supported by analyzing the set of proteins that function 
as efficient carriers and bear high affinity MHC-II binder peptides. Most of these 
peptides do not contain lysines (and the conjugation should not influence their 
high efficacy as carrier), but it was interesting to evidence that spr96/2021 that 
contains in the sequence of the spr2021 predicted high affinity MHC-II binder 
peptides with lysines induced an anti-Lam antibody titer significantly high, that is 
not the case of the spr2021. The same senario was observed from the GNA2091-
fHbp carrier protein.  
With the attempt to confirm the influence of glycosylation extent of MHC-II 
presenting peptides on the efficacy of the carrier, spr96/2021, spr2021 as well as 
the new fusion protein spr2021/96 were selected as a model to validate our 
hypothesis. We first showed that the three proteins induced a similar strong 
immune response in agreement  with the presence of high affinity predicted MHC-
II peptides identified. The observed immunogenicity did not increase when 
adjuvant was co-administrated, a situation that is quite different from what 
observed with CRM197. These aspects led us to speculate that even if factors, 
such as binding, internalization or processing may be involved in the immune 
response, the selected model is not highly affected by them. 
The three protein carriers were randomly conjugated with laminarin and their 
ability to induce an immune response against the polysaccharide antigen was 
tested. As previously showed, the fusion spr96/2021 showed a high IgG anti-
laminarin antibody titer when compared to the spr2021. Curiously, the new 
conjugate tested spr2021/96 did not display a similar immunogenicity of its 
counterparty spr96/2021. To evaluate the extend of conjugation of the carrier, we 
used a new in house method, combining a chemical deglycosylation and mass 
spectrometry technique. We were able to identify a different pattern of 
glycosylation for the three constructs. In agreement to the hypothesis that 
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glycosylation on the MHC-II predicted peptides influences the efficacy of the 
carrier.  
With the aim to improve to efficacy of the spr2021/96 and spr2021 carriers, we 
generated mutants in which the lysine residues involved in the conjugation were 
substituted with arginine residues. Moreover, insertion of predicted MHC-II 
peptide from the CRM197 protein was also inserted as spacer between the 
spr2021 and spr0096 proteins. As a second strategy, we selected another carrier 
protein, the GNA2091-fHbp in which the linker between the GNA2091 and fHbp 
protein was substituted with the predicted CRM197 MHC-II peptide and with one of 
the predicted spr2021 MHC-II peptide. All the mutated proteins showed a high 
level of immunogenicity comparable to the native forms. All the mutant conjugates 
were tested in mice for evaluating their ability to generate an immune response 
against the polysaccharide antigen. No increase in the immunogenicity was 
observed when the mutant conjugates were tested in mice. In all the tested group 
mice, a broad range of immune response was observed with the administration of 
the same conjugate; this wide range of immunogenicity together with the low IgG 
titer obtained for different mice in the same group increased the confidence 
interval for the GMT value obtained, implying the impossibility of applying any 
statistical analyses in order to identify differences among the constructs. The 
conjugates generated were deeply characterized and no differences were 
identified in term of sugar and protein/sugar ratio compared to the previous 
reported data49. Also the same strand, age and sex of mice was maintained to 
avoid any change in the immunogenicity response. The still low immunogenicity 
after the modification made on the carrier proteins could be due to the high 
number of predicted MHC-II peptides with a medium affinity, identified for the S. 
pneumoniae constructs that have not been taken into account in this study. Much 
effort was put in the identification of the peptides presented to the MHC-II for 
confirming the data obtained from the prediction software and the binding of the 
predicted peptides to the MHC-II. Mass spectrometry was extensively used for the 
detection of peptides presented by major histocompatibility complex class I and II, 
allowing rapid identification of a high number of peptides in a single 
experiment85,86.  
However, the analysis of MHC I and II peptides ligands from cells isolated in 
mouse was very challenging especially regarding the cost and amount of work 
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involved in each experiment. A high number of APCs were generally needed (in 
the order of 5 to 10 billion of APCs). Collecting a so high number of APCs 
required sacrificing from 50 to 100 mice87. Nevertheless, some laboratories were 
able to reduce the number of mice used allowing a reduction in term of amount of 
work. For instance, in vivo enrichment of mouse spleen DCs by Flt3L-B6 
melanoma treatment was described, expanding the subset of dendritic cells of 
around 10 fold88. Even if it is possible to reduce the amount of mice necessary, 
other limitations came with the subsequent step of purification and identification. 
The techniques used for the purification of the MHC bounded peptides required 
an immunoaffinity purification, which is highly specific but come with the cost of a 
very low yield89. A further restriction of this approach, is the unpredictable 
cleavage sites of the peptides generated for the presentation to the MHC 
complex. The cleavage generated by specific proteases, led to have known C-
terminus amino acid facilitating the MS/MS data analysis. Because of the 
impossibility of predicting the C-terminus region on these analyses, all the 20 
amino acid must have been considered as potential terminal residues, increasing 
the possibility in misidentifying the peptides. The main limitation in our case was 
due to the unfeasibility to have a so high number of mice and/or to use 
hematopoietic factors such as the Flt3L for enhancing the number of APCs. We 
were forced to limit our experiments to the use of 10 mice, in which all the 
splenocytes (dendritic cells, B lymphocytes, macrophages) were collected. Briefly, 
the splenocytes were infected with the protein spr96/2021, after 6h of infection, 
the cells were lysated and the MHC-II bounded peptides were purified using an 
immunoaffinity purification. The sample was then analyzed by mass spectrometry 
but no peptides from spr96/2021 were identified. The impossibility to perform 
experiments with a higher number of mice and the intrinsic limitation of the 
experiment above described prevented to verify that the two peptides predicted 
with a high predicted affinity for the MHC-II complex were empirically presented 
on the MHC-II. Due to the failure in identifying the MHC-II bounded peptides we 
were forced to rely only on the prediction software. Future study will be necessary 
to well define the role played by glycosylation in generating a memory response. 
Other approaches that may be used to study the influence of glycosylation in 
developing an immune response, and the role played by the glycosylation on 
MHC-II presented peptides, may be accomplished by using specific glycosylation 
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on the T cell epitopes of interest. Recently, an in vivo conjugation process for the 
generation of the so called bioconjugate vaccines have been developed90. This 
technology allows the biosynthesis of polysaccharide and carrier proteins in E. 
coli cells with the subsequent in vivo coupling of the carrier to the polysaccharide 
by using a specific oligosaccharyl transferase enzyme from the N-linked 
glycosylation system of Campylobacter91,92. Without going to much in detail on 
this engineered glycosylation process, the antigenic oligosaccharide can be 
enzymatically introduced on the Asparagine residues of the consensus sequence 
D/E-Xaa-N-Xaa-S/T, where Xaa can be any amino acid except Proline. The 
consensus sequence was inserted into different proteins such as EPA, Hla that 
are not glycosylated in their original organism, leading to develop of bioconjugate 
candidate vaccines against Staphylococcous aureus and Shigella flexneri 2a93,94. 
The consensus sequence used to generate the bioconjugates could be inserted in 
carrier proteins containing predicted MHC-II peptides of high affinity, modulating 
in a specific way the site of conjugation. Using this technology it will be possible to 
understand the rule played by the glycosylation on specific T cell epitope when 
glycosylated and correlate the IgG titer to the affinity of the predicted MHC-II 
peptides. 
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